ZEVRA THERAPEUTICS

Company snapshot

We are a purpose-driven, commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requ

• 1 approved product(s) across US/EU regulatory metadata.
• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for ZEVRA THERAPEUTICS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ZEVRA THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   Sodium phenylbutyrate — Phase 2

2. Jun 8, 2026 Clinical update

   Sodium phenylbutyrate — Phase 1

3. Jun 5, 2026 Clinical update

   KP415 oral capsule — Phase 3

4. May 23, 2026 Clinical update

   Serdexmethylphenidate — Phase 2

5. Mar 18, 2025 Patent grant

   Gamma-hydroxybutyrate delivering compounds and processes for making and using them

View all clinical trial activity →

• What is ZEVRA THERAPEUTICS?

  ZEVRA THERAPEUTICS is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker ZVRA. Primary therapeutic focus areas include ADHD, Idiopathic Hypersomnia, Combined D,L-2-hydroxyglutaric Aciduria, Medium-chain Acyl-CoA Dehydrogenase Deficiency. NovaPharma

• Is ZEVRA THERAPEUTICS publicly traded?

  Yes. ZEVRA THERAPEUTICS is listed with ticker ZVRA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ZEVRA THERAPEUTICS develop or market?

  We link 6 drug profile(s) where ZEVRA THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/zevra-therapeutics-inc#company-drugs.

• What are the latest developments for ZEVRA THERAPEUTICS?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ZEVRA THERAPEUTICS focus on?

  ZEVRA THERAPEUTICS focuses on ADHD, Idiopathic Hypersomnia, Combined D,L-2-hydroxyglutaric Aciduria based on our analysis of their pipeline programs and drug development activities.